Aldosterone synthase

Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results

Retrieved on: 
Monday, May 17, 2021

Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.

Key Points: 
  • Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
  • Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.
  • Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements.
  • Angion undertakes no obligation to update any forward-looking statement in this press release, except as required by law.\nThree Months Ended March 31,\n'

Angion to Participate in Upcoming March Investment Conferences

Retrieved on: 
Wednesday, February 24, 2021

Dr. Jay Venkatesan, Angions President and CEO, will also participate in a panel focused on kidney diseases at the Cowen 41st Annual Health Care Conference.

Key Points: 
  • Dr. Jay Venkatesan, Angions President and CEO, will also participate in a panel focused on kidney diseases at the Cowen 41st Annual Health Care Conference.
  • All three virtual investor conferences will take place in March 2021.
  • Angion is also currently evaluating ANG-3070, a tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in Phase 1.
  • Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor.

CinCor Pharma Announces First Patient Dosed with CIN-107 in Phase 2 Study in Treatment Resistant Hypertensive Subjects

Retrieved on: 
Tuesday, October 20, 2020

CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study.

Key Points: 
  • CINCINNATI, Oct. 20, 2020 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor), a clinical-stage biopharmaceutical company developing medications targeting cardiovascular disease, announced today that they have dosed the first subject in the brigHTN study.
  • The brigHTN study is a Phase 2 clinical trial evaluating the blood pressure lowering effects of CIN-107, a novel, once daily, and highly selective aldosterone synthase inhibitor (ASI) in subjects with treatment resistant hypertension.
  • CIN-107 is currently being developed for both treatment resistant hypertension and primary aldosteronism (PA).
  • CIN-107 represents a new class of anti-hypertensive agents that has the possibility of providing significant anti-hypertensive effects to treatment resistant patients, as well as to the broader hypertensive population.

PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

Retrieved on: 
Monday, January 13, 2020

PhaseBio will designate the lead development compound as PB6440, which PhaseBio plans to develop for treatment-resistant hypertension.

Key Points: 
  • PhaseBio will designate the lead development compound as PB6440, which PhaseBio plans to develop for treatment-resistant hypertension.
  • Terms of the agreement include an upfront payment by PhaseBio, development, approval, and net sales milestones and tiered royalties on global net sales.
  • PB6440 demonstrated dose-dependent aldosterone reduction without a significant increase in 11-deoxycorticosterone or deoxycortisol in both rodent and primate models.
  • PB6440 is a highly selective aldosterone synthase inhibitor being developed for treatment-resistant hypertension.